Skip to main content

Table 1 Baseline Characteristics

From: Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

Patient Characteristics Total (N = 157)
Age, median (range), y 66 (27–87)
Race, No. (%)
 White 142 (90.5)
 Black or African American 7 (4.5)
 Asian 3 (1.9)
 Native Hawaiian/Pacific Islander 1 (0.6)
 Other 4 (2.5)
Diagnosis, No. (%)
 Adenocarcinoma 108 (68.8)
 Squamous 45 (28.7)
 Other 4 (2.5)
Sex, No. (%)
 Female 74 (47.1)
 Male 83 (52.9)
Prior chemotherapy lines, No. (%)
 0 29 (18.5)
 1 78 (49.7)
 2 34 (21.7)
 ≥3 16 (10.2)
ECOG performance status, No. (%)
 0 40 (25.5)
 1 75 (47.8)
 2 37 (23.5)
 3 5 (3.2)
CNS disease, No. (%)
 Yes 54 (34.4)
 No 103 (65.6)
Immunotherapy drug, No. (%)
 Nivolumab 146 (93.0)
 Pembrolizumab 11 (7.0)
Immune adverse effects, No. (%)
 No 98 (62.4)
 Yes 59 (37.6)